Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
LabTau, INSERM U1032, Lyon, France.
World J Urol. 2023 Dec;41(12):3527-3533. doi: 10.1007/s00345-023-04643-1. Epub 2023 Oct 17.
To assess a region-of-interest-based computer-assisted diagnosis system (CAD) in characterizing aggressive prostate cancer on magnetic resonance imaging (MRI) from patients under active surveillance (AS).
A prospective biopsy database was retrospectively searched for patients under AS who underwent MRI and subsequent biopsy at our institution. MRI lesions targeted at baseline biopsy were retrospectively delineated to calculate the CAD score that was compared to the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 score assigned at baseline biopsy.
186 patients were selected. At baseline biopsy, 51 and 15 patients had International Society of Urological Pathology (ISUP) grade ≥ 2 and ≥ 3 cancer respectively. The CAD score had significantly higher specificity for ISUP ≥ 2 cancers (60% [95% confidence interval (CI): 51-68]) than the PI-RADS score (≥ 3 dichotomization: 24% [CI: 17-33], p = 0.0003; ≥ 4 dichotomization: 32% [CI: 24-40], p = 0.0003). It had significantly lower sensitivity than the PI-RADS ≥ 3 dichotomization (85% [CI: 74-92] versus 98% [CI: 91-100], p = 0.015) but not than the PI-RADS ≥ 4 dichotomization (94% [CI:85-98], p = 0.104). Combining CAD findings and PSA density could have avoided 47/184 (26%) baseline biopsies, while missing 3/51 (6%) ISUP 2 and no ISUP ≥ 3 cancers. Patients with baseline negative CAD findings and PSAd < 0.15 ng/mL who stayed on AS after baseline biopsy had a 9% (4/44) risk of being diagnosed with ISUP ≥ 2 cancer during a median follow-up of 41 months, as opposed to 24% (18/74) for the others.
The CAD could help define AS patients with low risk of aggressive cancer at baseline assessment and during subsequent follow-up.
评估基于感兴趣区域的计算机辅助诊断系统(CAD)在识别主动监测(AS)患者的磁共振成像(MRI)上侵袭性前列腺癌的能力。
回顾性搜索了在我院接受 MRI 检查和后续活检的 AS 患者的前瞻性活检数据库。对基线活检时靶向的 MRI 病变进行回顾性勾画,计算 CAD 评分,并与基线活检时分配的前列腺影像报告和数据系统(PI-RADS)第 2 版评分进行比较。
共纳入 186 例患者。在基线活检时,51 例和 15 例患者的国际泌尿病理学会(ISUP)分级分别为≥2 级和≥3 级癌症。CAD 评分对 ISUP≥2 级癌症的特异性明显高于 PI-RADS 评分(≥3 级二分法:24%[95%置信区间(CI):17-33],p=0.0003;≥4 级二分法:32%[CI:24-40],p=0.0003)。它的敏感性明显低于 PI-RADS≥3 级二分法(85%[CI:74-92]与 98%[CI:91-100],p=0.015),但与 PI-RADS≥4 级二分法无差异(94%[CI:85-98],p=0.104)。结合 CAD 发现和 PSA 密度可以避免 184 例基线活检中的 47 例(26%),但漏诊了 51 例 ISUP 2 级中的 3 例(6%)和 ISUP≥3 级癌症。在基线时 CAD 结果为阴性且 PSA 密度<0.15ng/mL 的患者继续进行 AS 治疗,在中位随访 41 个月期间,其诊断为 ISUP≥2 级癌症的风险为 9%(4/44),而其他患者的风险为 24%(18/74)。
CAD 可帮助在基线评估和后续随访中确定具有低侵袭性癌症风险的 AS 患者。